Monday, November 20, 2017 10:15 PM ET
Significant Sale Slows Insider Buying Trend over Last Quarter in Incyte (INCY)
There was a notable sale of shares of Incyte by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Dr Paul A Friedman, Director — sold 28,507 shares in the company having a market value of approximately $3,000,077. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the purchase of 100,000 company shares and the sale of 82,718 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 11,225 shares and have averaged 35,204 shares per transaction over this time period.
The number of insider buy/sell trades at Incyte is higher than that of the 188 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 202 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by Incyte insiders is lower than its peers. Within the peer group there were 25,483,921 shares purchased and 31,875,294 shares sold with company insiders having sold 31,640 shares on average over this time period.
For the purpose of evaluating significant insider buying and selling all trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data sourced to compose and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.